Patent ID: 11873338
Assignee: MERUS N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 7:
8. A method of purging CLEC12A positive hemopoietic cells from a subject and repopulating the hemopoietic system of said subject with normal CLEC12A positive cells, the method comprising administering to the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A thereby killing CLEC12A positive malignant cells, and stimulating hemopoietic stem cells and/or hemopoietic progenitor cells of said subject to repopulate said hemopoietic system with newly formed hemopoietic stem cell derived CLEC12A positive cells, wherein the first administration is a subtherapeutic amount of bispecific antibody.